JAK1 promotes HDV replication and is a potential target for antiviral therapy. - Institut de recherche sur les maladies virales et hépatiques Accéder directement au contenu
Article Dans Une Revue Journal of hepatology Année : 2024

JAK1 promotes HDV replication and is a potential target for antiviral therapy.

Résumé

Chronic co-infection with HBV and HDV leads to the most aggressive form of chronic viral hepatitis. To date, no treatment induces efficient viral clearance, and a better characterization of virus-host interactions is required to develop new therapeutic strategies. Using loss-of-function strategies, we validated the unexpected proviral activity of Janus kinase 1 (JAK1) - a key player in innate immunity - in the HDV life cycle and determined its mechanism of action on HDV through various functional analyses including co-immunoprecipitation assays. We confirmed the key role of JAK1 kinase activity in HDV infection. Moreover, our results suggest that JAK1 inhibition is associated with a modulation of ERK1/2 activation and S-HDAg phosphorylation, which is crucial for viral replication. Finally, we showed that FDA-approved JAK1-specific inhibitors are efficient antivirals in relevant in vitro models including primary human hepatocytes. Taken together, we uncovered JAK1 as a key host factor for HDV replication and a potential target for new antiviral treatment. Chronic hepatitis D is the most aggressive form of chronic viral hepatitis. As no curative treatment is currently available, new therapeutic strategies based on host-targeting agents are urgently needed. Here, using loss-of-function strategies, we uncover an unexpected interaction between JAK1, a major player in the innate antiviral response, and HDV infection. We demonstrated that JAK1 kinase activity is crucial for both the phosphorylation of the delta antigen and the replication of the virus. By demonstrating the antiviral potential of several FDA-approved JAK1 inhibitors, our results could pave the way for the development of innovative therapeutic strategies to tackle this global health threat.
Fichier principal
Vignette du fichier
islandora_170410.pdf (4.29 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04524176 , version 1 (27-03-2024)

Identifiants

Citer

Margaux Heuschkel, Charlotte Bach, Laura Meiss-Heydmann, Emma Gerges, Emanuele Felli, et al.. JAK1 promotes HDV replication and is a potential target for antiviral therapy.. Journal of hepatology, 2024, 80 (2), pp.220-231. ⟨10.1016/j.jhep.2023.10.030⟩. ⟨hal-04524176⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More